Literature DB >> 22307232

Anetodermic pilomatricoma: molecular characteristics and trauma in the development of its bullous appearance.

Li Li1, Yueping Zeng, Kai Fang, Yu Xiao, Hongzhong Jin, Heather Ray, Jiang Chen.   

Abstract

Pilomatricoma is a common benign neoplasm of the skin characterized by a solid cutaneous nodule of hair matrix origin. The anetodermal or lymphangiectatic variant of pilomatricoma is rare, and its bullous appearance is often associated with attenuated collagen and elastic fibrils and dilated lymphatic vessels in the overlying dermis. However, the tumors of anetodermic pilomatricoma have never been characterized at the molecular level, and the exact mechanism for their development is unknown. In this study, we evaluated histological and molecular features of a bullous pilomatricoma along with 5 control tumors and determined that tumors of both anetodermic and control pilomatricoma comprise similar molecular features, such as nuclear lymphoid enhancer binding factor 1 (LEF1) localization and the expression of keratins. In addition, we associated the development of the anetodermic pilomatricoma with mechanical trauma, scar tissue formation, and increased numbers of blood and lymphatic vessels. This study suggests that the development of the anetodermic form of pilomatricoma is unlikely to be associated with the intrinsic properties of the tumor but with the mechanical trauma that disrupts the dermal integrity and vascular microenvironment.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22307232      PMCID: PMC3360824          DOI: 10.1097/DAD.0b013e31823583f5

Source DB:  PubMed          Journal:  Am J Dermatopathol        ISSN: 0193-1091            Impact factor:   1.533


  18 in total

1.  Pilomatricoma with a bullous appearance.

Authors:  S Inui; R Kanda; S Hata
Journal:  J Dermatol       Date:  1997-01       Impact factor: 4.005

2.  De Novo hair follicle morphogenesis and hair tumors in mice expressing a truncated beta-catenin in skin.

Authors:  U Gat; R DasGupta; L Degenstein; E Fuchs
Journal:  Cell       Date:  1998-11-25       Impact factor: 41.582

3.  A common human skin tumour is caused by activating mutations in beta-catenin.

Authors:  E F Chan; U Gat; J M McNiff; E Fuchs
Journal:  Nat Genet       Date:  1999-04       Impact factor: 38.330

4.  Pilomatrix carcinomas contain mutations in CTNNB1, the gene encoding beta-catenin.

Authors:  Alexander J F Lazar; Eduardo Calonje; Wayne Grayson; Angelo P Dei Tos; Martin C Mihm; Mark Redston; Phillip H McKee
Journal:  J Cutan Pathol       Date:  2005-02       Impact factor: 1.587

5.  Bullous appearance of pilomatricoma.

Authors:  Emel Fetil; M Cüneyt Soyal; Adnan Menderes; Banu Lebe; Ali Tahsin Güneş; Sebnem Ozkan
Journal:  Dermatol Surg       Date:  2003-10       Impact factor: 3.398

6.  Pilomatrixoma: clinicopathologic study of 51 cases with emphasis on cytologic features.

Authors:  Jun Wang; Camilla J Cobb; Sue E Martin; Rose Venegas; Nancy Wu; Timothy S Greaves
Journal:  Diagn Cytopathol       Date:  2002-09       Impact factor: 1.582

7.  A clinical review of 209 pilomatricomas.

Authors:  C G Julian; P W Bowers
Journal:  J Am Acad Dermatol       Date:  1998-08       Impact factor: 11.527

8.  Pilomatrixoma: a review of 346 cases.

Authors:  Ashkan Pirouzmanesh; John F Reinisch; Ignacio Gonzalez-Gomez; Ebonie M Smith; John G Meara
Journal:  Plast Reconstr Surg       Date:  2003-12       Impact factor: 4.730

9.  Pilomatricoma of the head and neck: a retrospective review of 179 cases.

Authors:  Ming-Ying Lan; Ming-Chin Lan; Ching-Yin Ho; Wing-Yin Li; Ching-Zong Lin
Journal:  Arch Otolaryngol Head Neck Surg       Date:  2003-12

10.  Pilomatricoma with a bullous appearance.

Authors:  Jiang Yiqun; Sun Jianfang
Journal:  J Cutan Pathol       Date:  2004-09       Impact factor: 1.587

View more
  1 in total

1.  [Anetodermic pilomatricoma. Uncommon variant of a common childhood adnexal tumor].

Authors:  F Karademir; A Kerstan; H Hamm
Journal:  Hautarzt       Date:  2014-01       Impact factor: 0.751

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.